Latest news with #NexoBrid®
Globe and Mail
12-03-2025
- Health
- Globe and Mail
Burn Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
The Key Burn Pain Companies in the market include - Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others. DelveInsight's 'Burn Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Burn Pain, historical and forecasted epidemiology as well as the Burn Pain market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Burn Pain Market Report: The Burn Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In August 2024, MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients from newborns to 18 years old with deep partial- and full-thickness thermal burns. This approval expands NexoBrid's authorization for all age groups in the U.S., aligning with its approvals in the European Union and Japan. In 2023, the US maintained the largest market share among the 7MM, reaching USD 140 million. Projections indicate that this trend will persist, with the US expected to further strengthen its market dominance and remain the leading player by 2034. In 2023, Germany and the UK in the EU4 and the UK both achieved market shares exceeding USD 20 million, with France following closely behind. In contrast, Italy had the smallest market share among these regions during the same period. Opioid analgesics dominated the current treatment market for both inpatient and outpatient care, with an estimated market value of approximately USD 130 million in 2023. In 2023, the US recorded over 2 million incident cases of burns, with numbers expected to rise by 2034. In 2023, approximately 0.4 million treated incident burn cases requiring pain management therapies were reported in the US, with expectations for change during the study period from 2020 to 2034. The gender distribution indicates a male dominance across the 7MM, with around 0.29 million male cases and 0.26 million female cases reported in the US in 2023. Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others The Burn Pain epidemiology based on etiology-specific cases analyzed that Etiology Specific Incident Cases of Burns is classified into Flame, Contact, Scald, Electrical, Chemical, and Others The Burn Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Burn Pain pipeline products will significantly revolutionize the Burn Pain market dynamics. Burn Pain Overview An organic tissue injury known as a burn is mostly brought on by heat, radiation, radioactivity, electricity, friction, or chemical contact. Get a Free sample for the Burn Pain Market Report - Burn Pain Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Burn Pain Epidemiology Segmentation: The Burn Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Burn Pain Prevalent Cases of Burn Pain by severity Gender-specific Prevalence of Burn Pain Diagnosed Cases of Episodic and Chronic Burn Pain Download the report to understand which factors are driving Burn Pain epidemiology trends @ Burn Pain Epidemiology Forecast Burn Pain Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Burn Pain market or expected to get launched during the study period. The analysis covers Burn Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Burn Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Burn Pain Therapies and Key Companies Burn Pain Market Strengths The increasing incidence of patients with burns is expected to propel the treatment market in the future, adding opportunities for new pharma players Burn Pain Market Opportunities The rising incidence of burn pain indicates increasing pharmacological treatment demands, thereby crafting lucrative opportunities for new pharma players Scope of the Burn Pain Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others Burn Pain Therapeutic Assessment: Burn Pain current marketed and Burn Pain emerging therapies Burn Pain Market Dynamics: Burn Pain market drivers and Burn Pain market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Burn Pain Unmet Needs, KOL's views, Analyst's views, Burn Pain Market Access and Reimbursement Table of Contents 1. Burn Pain Market Report Introduction 2. Executive Summary for Burn Pain 3. SWOT analysis of Burn Pain 4. Burn Pain Patient Share (%) Overview at a Glance 5. Burn Pain Market Overview at a Glance 6. Burn Pain Disease Background and Overview 7. Burn Pain Epidemiology and Patient Population 8. Country-Specific Patient Population of Burn Pain 9. Burn Pain Current Treatment and Medical Practices 10. Burn Pain Unmet Needs 11. Burn Pain Emerging Therapies 12. Burn Pain Market Outlook 13. Country-Wise Burn Pain Market Analysis (2020–2034) 14. Burn Pain Market Access and Reimbursement of Therapies 15. Burn Pain Market Drivers 16. Burn Pain Market Barriers 17. Burn Pain Appendix 18. Burn Pain Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
24-02-2025
- Business
- Yahoo
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register here. A replay of the event will also be posted to MediWound's website on the Events & Presentations page of the Investors section. In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their TD Cowen representative to schedule a meeting. About MediWound MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries. MediWound's first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available $375+ million drug for wound debridement, presenting a unique opportunity for significant market growth. For more information visit and follow us on LinkedIn. MediWound Contacts: Hani Luxenburg Daniel Ferry Chief Financial Officer Managing Director MediWound Ltd. LifeSci Advisors, LLC ir@ daniel@ Contact: Ellie Hanson FINN Partners for MediWound in to access your portfolio
